These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 16618754

  • 1. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
    Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J, Wang Y, Qian Q, Qian C, Wu J, Liu XY.
    Cancer Res; 2006 Apr 15; 66(8):4291-8. PubMed ID: 16618754
    [Abstract] [Full Text] [Related]

  • 2. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.
    Liu XY, Qiu SB, Zou WG, Pei ZF, Gu JF, Luo CX, Ruan HM, Chen Y, Qi YP, Qian C.
    Mol Ther; 2005 Apr 15; 11(4):531-41. PubMed ID: 15771956
    [Abstract] [Full Text] [Related]

  • 3. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
    Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C, Liu X.
    Hepatology; 2004 May 15; 39(5):1371-81. PubMed ID: 15122766
    [Abstract] [Full Text] [Related]

  • 4. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
    Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, Wang Y, He L, Qian C, Qian Q, Liu X.
    Cancer Gene Ther; 2006 Nov 15; 13(11):1011-22. PubMed ID: 16799468
    [Abstract] [Full Text] [Related]

  • 5. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X, Lu Q, Zhao Y, Ren Z, Ren XW, Qiu QH, Tong Y, Liang M, Hu F, Chen HZ.
    Int J Mol Med; 2005 Dec 15; 16(6):1179-84. PubMed ID: 16273304
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
    Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B.
    Cancer Res; 2001 Apr 15; 61(8):3330-8. PubMed ID: 11309289
    [Abstract] [Full Text] [Related]

  • 7. Targeting gene-virotherapy of cancer.
    Liu XY, Gu JF.
    Cell Res; 2006 Jan 15; 16(1):25-30. PubMed ID: 16467873
    [Abstract] [Full Text] [Related]

  • 8. Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer.
    Zhang Y, Qin X, Zhang Y, Zhao L, Wang Y, Liu X, Yao L.
    J Cancer Res Clin Oncol; 2008 Feb 15; 134(2):219-26. PubMed ID: 17632733
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.
    Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B.
    Gene Ther; 2002 Sep 15; 9(18):1262-70. PubMed ID: 12215894
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S, Singh TR, Srivastava RK.
    Prostate; 2004 Sep 15; 61(1):35-49. PubMed ID: 15287092
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.
    Li X, Marani M, Yu J, Nan B, Roth JA, Kagawa S, Fang B, Denner L, Marcelli M.
    Cancer Res; 2001 Jan 01; 61(1):186-91. PubMed ID: 11196158
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Killing effect of Ad.TERT-TRAIL on tumor cell lines and its mechanism].
    Tang YX, Chen Y, Gu JF, Qi R, Zou WG, Jiang LL, Liu XY.
    Ai Zheng; 2005 May 01; 24(5):536-42. PubMed ID: 15890093
    [Abstract] [Full Text] [Related]

  • 16. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
    Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J, Fang B.
    Gene Ther; 2002 Oct 01; 9(20):1379-86. PubMed ID: 12365003
    [Abstract] [Full Text] [Related]

  • 17. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X, Yang M, Wei RC, Zeng Y, Gu JF, Huang WD, Yang DQ, Li HL, Ding M, Wei N, Zhang KJ, Xu B, Liu XR, Qian QJ, Liu XY.
    Gene Ther; 2011 Aug 01; 18(8):765-77. PubMed ID: 21412282
    [Abstract] [Full Text] [Related]

  • 18. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
    Liu X, Cao X, Wei R, Cai Y, Li H, Gui J, Zhong D, Liu XY, Huang K.
    Cancer Gene Ther; 2012 Jan 01; 19(1):49-57. PubMed ID: 21979578
    [Abstract] [Full Text] [Related]

  • 19. Targeting gene-virotherapy of cancer and its prosperity.
    Liu XY.
    Cell Res; 2006 Nov 01; 16(11):879-86. PubMed ID: 17102812
    [Abstract] [Full Text] [Related]

  • 20. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
    Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA, Fang B.
    Cancer Res; 2002 Jul 01; 62(13):3620-5. PubMed ID: 12097263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.